Observations placeholder
Zolinza
Identifier
020470
Type of Spiritual Experience
Number of hallucinations: 1
Background
A description of the experience
Vorinostat (rINN) also known as suberanilohydroxamic acid (suberoyl+anilide+hydroxamic acid abbreviated as SAHA) is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities.
Vorinostat is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after treatment with other medicines.
On Feb, 25, 2016: 365 people reported to have side effects when taking Zolinza. Among them, 1 people (0.27%) has Hallucination.
Time on Zolinza when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
On Feb, 25, 2016: 365 people reported to have side effects when taking Zolinza. Among them, 32 people (8.77%) have Death.
Time on Zolinza when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 86.21% | 6.90% | 3.45% | 3.45% | 0.00% | 0.00% | 0.00% |